The FDA has approved additional indications for EquivaBone, a hard-setting osteoinductive osteoinductive bone graft substitute from Etex Corp., according to a release from Etex.
EquivaBone is now additionally indicated for use in posterolateral spine fusion, combining the certified osteoinductivity of DBM with the handling and hard setting characteristics of Etex calcium phosphate osteoconductive scaffold.
The clearance also allows EquivaBone to be mixed with autologous blood to create a viscous putty can then be molded and packed or injected into a defect.
Read Etex’s release on FDA approval of EquivaBone.
From findings on cervical disc replacement to total knee replacement, Becker’s reported on eight spine and orthopedic studies since March…
Researchers at UMass Chan Medical School in Worcester, Mass., have created an algorithm to predict total knee replacement outcomes in…
Orthopaedic Solutions Management has acquired Orlando Hand Surgical Associates, marking its eighth acquisition. OHSA was founded in 2000 and has…
Comments are closed.